Baseline characteristics of patients
| Knee OA (n = 914) | Hip OA (n = 310) | |||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| *Non-steroidal anti-inflammatory drugs (before the start of the study); †other than NSAIDs (before the start of the study); ‡chondroitin sulphate, diacerhein, or avocado soybean unsaponifiables. | ||||
| Age (years) | 67.8 | 10.2 | 65.7 | 10.8 |
| Weight (kg) | 75.2 | 14.2 | 72.2 | 14.0 |
| Height (cm) | 163.6 | 8.7 | 164.8 | 8.2 |
| Body mass index (kg/m2) | 28.1 | 4.7 | 26.5 | 4.1 |
| Disease duration (years) | 4.8 | 5.8 | 3.4 | 4.8 |
| Pain score (0–100 mm VAS) | ||||
| Week 0 | 58.3 | 16.9 | 56.7 | 17.4 |
| Change (week 0–week 4) | −24.5 | 22.1 | −18.7 | 21.8 |
| Patient global assessment (0–100 mm VAS) | ||||
| Week 0 | 58.7 | 19.1 | 58.6 | 16.5 |
| Change (week 0–week 4) | −24.0 | 24.6 | −19.5 | 23.5 |
| WOMAC function score (0–100) | ||||
| Week 0 | 42.9 | 16.6 | 45.9 | 17.1 |
| Change (week 0–week 4) | −11.6 | 14.4 | −10.8 | 14.1 |
| No | (%) | No | (%) | |
| Female sex | 637 | (69.7) | 189 | (61.0) |
| Kellgren and Lawrence grade | ||||
| II | 178 | (19.5) | 57 | (18.5) |
| III | 394 | (43.1) | 145 | (46.9) |
| IV | 342 | (37.4) | 107 | (34.6) |
| NSAID* intake during past 4 weeks | 262 | (28.8) | 97 | (31.3) |
| Analgesic intake† | 513 | (56.3) | 209 | (67.9) |
| Symptomatic slow acting drugs intake‡ | 311 | (34.1) | 123 | (39.8) |